860636P
Avanti
Glucosyl(β) Sphingosine-d5
Avanti Research™ - A Croda Brand
Synonym(s):
D-glucosyl-β-1,1′-D-erythro-sphingosine-d5
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
Recommended Products
form
powder
packaging
pkg of 1 × 1 mg (860636P-1mg)
manufacturer/tradename
Avanti Research™ - A Croda Brand
shipped in
dry ice
storage temp.
−20°C
SMILES string
[H][C@](/C=C/CCCCCCCCCCCC([2H])(C([2H])([2H])[2H])[2H])(O)[C@](N)([H])CO[C@H](O1)[C@H](O)[C@@H](O)[C@@H]([C@H]1CO)O
Application
Glucosyl(β) Sphingosine-d5 has been used as an internal standard for the quantification of lysohexosylceramide in various samples by liquid chromatography-tandem mass spectrometry.
Biochem/physiol Actions
Glucosyl sphingosine has an ability to regulate Ca2+ release in the brain microsomes. It acts as a potential biomarker for Gaucher disease (GD).
Packaging
5 mL Amber Glass Screw Cap Vial (860636P-1mg)
Legal Information
Avanti Research is a trademark of Avanti Polar Lipids, LLC
Storage Class Code
11 - Combustible Solids
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Glucosylsphingosine is a highly sensitive and specific biomarker for primary diagnostic and follow-up monitoring in Gaucher disease in a non-Jewish, Caucasian cohort of Gaucher disease patients
PLoS ONE, 8(11) (2013)
LC-MS/MS multiplex analysis of lysosphingolipids in plasma and amniotic fluid: a novel tool for the screening of sphingolipidoses and Niemann-Pick type C disease
PLoS ONE, 12(7) (2017)
LC-MS/MS multiplex analysis of lysosphingolipids in plasma and amniotic fluid: a novel tool for the screening of sphingolipidoses and Niemann-Pick type C disease
Testing, 12(7) (2017)
Journal of orthopaedic surgery and research, 14(1), 383-383 (2019-11-23)
Chronic fatigue (CFg) is a prevalent symptom in Gaucher disease (GD) at diagnosis (79%) and remains in a quarter of patients after years of therapy. Bone abnormalities are present in over 70% and peripheral neuropathy in about 11% of the
PloS one, 12(7), e0181700-e0181700 (2017-07-28)
The biological diagnosis of sphingolipidoses currently relies on the measurement of specific enzymatic activities and/or genetic studies. Lysosphingolipids have recently emerged as potential biomarkers of sphingolipidoses and Niemann-Pick type C in plasma. We developed a sensitive and specific method enabling
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service